The investigation follows a July 22, 2026, earnings release where Dr. Reddy's reported earnings per share of just $0.06. This figure was heavily weighed down by a ₹2.4 billion provision linked to out-of-specification semaglutide batches. CEO Erez Israeli attributed the margin compression to production challenges, including rejected batches, diminished sales, and the loss of production-linked incentives. Investors reacted sharply to the disclosure, driving the stock price down by $1.18 to close at $11.38 per share.

Pomerantz LLP is currently inviting affected shareholders to come forward as they evaluate potential claims of corporate misconduct and breaches of fiduciary duty. The firm, which maintains a global presence across major financial hubs including New York, London, and Tel Aviv, has a history of litigating high-stakes securities class actions. Investors seeking to participate in the inquiry may contact Danielle Peyton for further details regarding the ongoing legal assessment.